ArticleCancers2020
Evaluation of a Novel Liquid Fiducial Marker, BioXmark
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies.Pharmaceutics · 2025Review
- IR808-ATIPA: A Dual-Function Agent for Enhanced Computed Tomography Imaging and Radiotherapy Sensitization in Cervical Cancer Treatment.Biomaterials research · 2025Article
- Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination.Nanomaterials (Basel, Switzerland) · 2023Review
- Feasibility and guidelines for the use of an injectable fiducial marker (BioXmarkF1000Research · 2023Article
- BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial.Clinical and translational radiation oncology · 2023Article
- Precisely translating computed tomography diagnosis accuracy into therapeutic intervention by a carbon-iodine conjugated polymer.Nature communications · 2022Article
- A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology.Clinical and translational radiation oncology · 2022Article
- A liquid immunogenic fiducial eluter for image-guided radiotherapy.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
BioXmark
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.